Insulin Therapy in Type 2 Diabetes: Indications & Regimens
Insulin is not a treatment failure but a physiological necessity when β-cell function declines below the threshold to maintain glycemic targets. Modern guidelines position it flexibly.
ADA/EASD 2023 Indications for Insulin Initiation
- Symptomatic hyperglycemia / catabolism (weight loss, polyuria, ketosis) at any HbA1c.
- HbA1c >10% (86 mmol/mol) or >9% (75 mmol/mol) with symptoms – start insulin ± GLP-1 RA immediately.
- HbA1c >9% after 3 months on dual/triple oral therapy (metformin + 1–2 agents).
- Inability to use non-insulin agents (CKD, GI intolerance, contraindications, cost/access).
- Special situations: Pregnancy (GDM/T2D), perioperative, glucocorticoid therapy, hospitalization.
- Patient preference after informed discussion.
Common Initiation Regimens
| Regimen | Starting Dose | Titration | Best For |
|---|---|---|---|
| Basal Only (Glargine U100/U300, Degludec, Detemir) | 10 U or 0.1–0.2 U/kg | ↑2–4 U every 3–7 days to FPG target (80–130 mg/dL) | Most T2D; simple, low hypoglycemia, weight neutral |
| Basal + 1 Rapid (Basal-Bolus) | Basal as above + 4 U or 10% basal at largest meal | Adjust per meal PPG target (<180 mg/dL) | High postprandial excursions, erratic schedule |
| Premixed (70/30, 75/25) | 0.3–0.5 U/kg divided BID | Adjust per pre-meal glucose | Regular meals, limited titration ability, cost |
| GLP-1 RA + Basal Insulin (Fixed Ratio) | iGlarLixi (LixiLan), IDegLira (Xultophy) | Per product algorithm | Synergy; ↓weight, ↓hypo vs insulin alone |
Key Principles
- Continue metformin + SGLT2i/GLP-1 RA (cardiorenal benefits, ↓insulin dose/weight).
- Hypoglycemia prevention: Education, CGM, glucagon, liberalize targets if high risk (elderly, CKD, CVD, hypoglycemia unawareness).
- Weight management: Insulin causes ~2–4 kg gain; mitigate with GLP-1 RA/SGLT2i, diet, activity.
- CGM is standard of care for all on insulin (ADA 2023).
Barriers & Solutions
- Fear of injections → pens, short needles (4–5 mm), demo.
- Hypoglycemia fear → education, CGM, newer analogs (degludec, glargine U300).
- Cost → biosimilars, patient assistance, older insulins (NPH/Regular) if needed.
- Stigma → reframe as hormone replacement.
Insulin therapy is individualized, dynamic, and collaborative. Early initiation when indicated prevents glucotoxicity and preserves β-cells.
Diabetes - Related Articles
- Diabetes and Mood: Understanding Irritability and Emotional Changes
- Diabetes Diet & Sugar Management: A Comprehensive Guide
- Preventing Itching from Insulin Injections: A Guide for Diabetics
- Diabetes Care Team: Endocrinologists, PCPs, Educators, Dietitians & More
- Insulin & Exenatide Together: Safety, Risks & Dosage Adjustments
- Understanding Diabetes Insipidus (DI): Symptoms, Causes & Treatment
- Online Insulin Injection Training: A Guide for Healthcare Professionals
